ID: MRFR/Pharma/2884-HCR | February 2021 | Region: Global | 203 pages
Yeast infection is also known as candidiasis. Candidiasis is an infection caused by numerous types of yeast called Candida. The most common type of yeast causing infection is Candida albicans. This yeast is normally present on the skin, in the intestines and vagina, but under normal conditions it doesn’t cause infection. However, sometimes it can develop into an infection of the mouth, vagina or skin due to weak immune response, unhygienic conditions, and other factors.
Yeast infection can occur due to many reasons such as weak immunity, unhygienic conditions, and presence of a conducive environment for the growth of the associated microbes. In addition to infants, people suffering from diabetes, obesity, hypothyroidism, inflammatory disorders are also prone to catching yeast infection. The global yeast infection market is majorly driven by increasing prevalence of autoimmune diseases, continuously increasing geriatric population, and increasing number of patients suffering from HIV. According to the Joint United Nations Programme on HIV and AIDS (UNAIDS), by the end of 2015, approximately 36.7 million people worldwide were suffering from HIV/AIDS , out of which 1.8 million were children below 15 years. Moreover, rising demand for antifungal drugs and government support for research & development have fuelled the market growth. However, side effects of the treatment may hinder the growth of the market. The global yeast infection market is expected to grow at a CAGR of 5.2% during the forecasted period.
Figure: Global yeast infection market, by pathogen, 2016 (%)
Some of the key players in yeast infection market are Scynexis (US), Synmedic Laboratories (India), Merck & Co., Inc. (US), Astellas (Japan), Bayer AG (Germany), Mentis Pharma Ltd. (India), Abbott (US), Novartis AG (Switzerland), Pfizer Inc. (US), Sanofi (France), ALLERGAN (Ireland), AstraZeneca (UK)
The global yeast infection market is segmented on the basis of pathogen, types, treatment, and end users. On the basis of pathogens, the market is segmented into Candida albicans, Candida glabrata, Candida rugosa, and others.
On the basis of types, the market is categorized into vaginal yeast infection, skin yeast infection, throat yeast infection, and others.
On the basis of treatment, the market is segmented into drug treatment and surgery. Drug treatment is further classified into cream, ointment, tablet, and suppository.
On the basis of end users, the market is segmented into hospital, clinics, ambulatory centers and others.
The Americas account for the largest share in the global yeast infection market owing to presence of huge geriatric population and increasing number of patients suffering from immune diseases. According to the Autoimmune Registry, in 2012, approximately 14.7 million Americans were suffering from auto immune diseases.
Europe is the second largest market and holds a noticeable share in the global yeast infection market. The European market is expected to grow significantly during the forecast period owing to availability of advanced treatment facilities, skilled medical professionals, and government support for research & development.
Increasing prevalence of HIV in Asia Pacific region is the crucial factor for the market growth. Rising awareness about the infections and availability of new treatment methods drive the market in this region. In Asia Pacific, the market shows growth opportunities in China and India.
However, the Middle East & Africa is expected to show the least growth in this market due to some major factors such as lack of awareness about the yeast infections, limited access and availability of treatment facilities.
The report on the global yeast infection market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain deeper insight to the market and industry performance. The report gives a clear picture of the current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different market segments and regions
|Market Size||Significant Value|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Pathogen, Types, Treatment, and End users|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||Scynexis (US), Synmedic Laboratories (India), Merck & Co., Inc. (US), Astellas (Japan), Bayer AG (Germany), Mentis Pharma Ltd. (India), Abbott (US), Novartis AG (Switzerland), Pfizer Inc. (US), Sanofi (France), ALLERGAN (Ireland), AstraZeneca (UK)|
|Key Market Opportunities||New treatment methods|
|Key Market Drivers||
Frequently Asked Questions (FAQ) :
The projected CAGR is 5.2% for the forecast period (2018-2023).
The players are Synmedic Laboratories (India), Scynexis (US), Astellas (Japan), Bayer AG (Germany), Merck & Co., Inc. (US), Abbott (US), Mentis Pharma Ltd. (India), Sanofi (France), Novartis AG (Switzerland), Pfizer Inc. (US), AstraZeneca (UK), ALLERGAN (Ireland), and others.
What are the end users in the Yeast Infection Market?
Yeast Infection Market has types like a skin yeast infection, throat yeast infection, vaginal yeast infection, and others.
Americas would lead the Yeast Infection Market.
1 Report Prologue
2 Market Introduction
2.2 Scope of the Study
2.2.1 Research Objective
3 Research Methodology
3.2 Primary Research
3.3 Secondary research
3.4 Market Size Estimation
4 Market Dynamics
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
5. Market Factor Analysis
5.1 Porters five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain
5.3 Investment Feasibility Analysis
5.4 Price Factor Analysis
6 Global Yeast Infection Market, by Pathogens
6.2 Candida albicans
6.3 Candida glabrata
6.4 Candida rugosa
7 Global Yeast Infection Market, by Types
7.2 Vaginal Yeast Infection
7.3 Skin Yeast Infection
7.4 Throat Yeast Infection
8 Global Yeast Infection Market, by Treatment
8.1 Drug Treatment
9 Global Yeast Infection Market, by End User
9.4 Ambulatory Centers
10 Global Yeast Infection Market by Region
10.2.1 North America
10.2.2 Latin America
10.3.1 Western Europe
10.3.1.6 Rest of Western Europe
10.3.2 Eastern Europe
10.4 Asia Pacific
10.4.4 Republic of Korea
10.4.6 Rest of Asia-Pacific
10.5 The Middle East & Africa
10.5.1 United Arab Emirates
10.5.2 Saudi Arabia
10.5.6 Rest of Middle East & Africa
11 Company Landscape
11.2 Market share Analysis
11.3 Key Development & Strategies
11.3.1 Key Developments
12 Company Profiles
12.1.1 Company Overview
12.1.2 Product Overview
12.1.4 SWOT Analysis
12.2 Synmedic Laboratories
12.2.1 Company Overview
12.2.2 Product Overview
12.2.3 Financial Overview
12.2.4 Key Developments
12.2.5 SWOT Analysis
12.3 Merck & Co., Inc.
12.3.1 Company Overview
12.3.2 Product Overview
12.3.3 Financial Overview
12.3.4 Key Development
12.3.5 SWOT Analysis
12.4.1 Company Overview
12.4.2 Product/Business Segment Overview
12.4.3 Financial Overview
12.4.4 Key Development
12.4.5 SWOT Analysis
12.5 Bayer AG
12.5.1 Company Overview
12.5.2 Product Overview
12.5.3 Financial overview
12.5.4 Key Developments
12.6.1 Company Overview
12.6.2 Product Overview
12.6.3 Financial Overview
12.6.4 Key Developments
12.7 Novartis AG
12.7.2 Product Overview
12.7.4 Key Developments
12.7.5 SWOT Analysis
13 MRFR Conclusion
13.1 Key Findings
13.1.1 From CEO’s View Point
13.1.2 Unmet Needs of the Market
13.2 Key Companies to Watch
13.3 Prediction of Pharmaceutical Industry